Jacobs Levy Equity Management, Inc An2 Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 79,359 shares of ANTX stock, worth $107,928. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,359Holding current value
$107,928% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ANTX
# of Institutions
33Shares Held
13.5MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$7.82 Million3.62% of portfolio
-
Ra Capital Management, L.P. Boston, MA2MShares$2.72 Million0.03% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$2.11 Million0.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.42 Million0.0% of portfolio
-
Acuitas Investments, LLC446KShares$606,2640.23% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $26.4M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...